Empowered Funds LLC Grows Stock Holdings in iTeos Therapeutics, Inc. (NASDAQ:ITOS)

Empowered Funds LLC raised its position in shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS) by 5.0% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 69,072 shares of the company’s stock after buying an additional 3,305 shares during the quarter. Empowered Funds LLC owned about 0.19% of iTeos Therapeutics worth $530,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. nVerses Capital LLC raised its position in shares of iTeos Therapeutics by 212.5% in the 3rd quarter. nVerses Capital LLC now owns 2,500 shares of the company’s stock valued at $26,000 after purchasing an additional 1,700 shares during the last quarter. Point72 DIFC Ltd purchased a new position in shares of iTeos Therapeutics in the 3rd quarter valued at approximately $31,000. China Universal Asset Management Co. Ltd. raised its position in shares of iTeos Therapeutics by 60.4% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 7,024 shares of the company’s stock valued at $72,000 after purchasing an additional 2,646 shares during the last quarter. Clear Harbor Asset Management LLC purchased a new position in shares of iTeos Therapeutics in the 4th quarter valued at approximately $96,000. Finally, Virtu Financial LLC purchased a new position in shares of iTeos Therapeutics in the 3rd quarter valued at approximately $102,000. 97.16% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on ITOS. Wells Fargo & Company cut their price target on shares of iTeos Therapeutics from $31.00 to $19.00 and set an “overweight” rating on the stock in a report on Thursday, December 19th. HC Wainwright reiterated a “buy” rating and issued a $21.00 price target on shares of iTeos Therapeutics in a report on Thursday, January 16th. Finally, Wedbush reiterated an “outperform” rating and issued a $25.00 price target on shares of iTeos Therapeutics in a report on Friday, January 10th.

iTeos Therapeutics Price Performance

Shares of NASDAQ ITOS opened at $7.50 on Thursday. The stock has a market capitalization of $273.98 million, a price-to-earnings ratio of -2.38 and a beta of 1.38. iTeos Therapeutics, Inc. has a 12 month low of $7.06 and a 12 month high of $18.75. The firm’s 50 day simple moving average is $7.61 and its 200-day simple moving average is $10.11.

iTeos Therapeutics Company Profile

iTeos Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.